Tags

Type your tag names separated by a space and hit enter

Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.
Hum Vaccin Immunother. 2015; 11(7):1626-33.HV

Abstract

Studies that have evaluated the influenza vaccine effectiveness (VE) to prevent laboratory-confirmed influenza B cases are uncommon, and few have analyzed the effect in preventing hospitalized cases. We have evaluated the influenza VE in preventing outpatient and hospitalized cases with laboratory-confirmed influenza in the 2012-2013 season, which was dominated by a vaccine-matched influenza B virus. In the population covered by the Navarra Health Service, all hospitalized patients with influenza-like illness (ILI) and all ILI patients attended by a sentinel network of general practitioners were swabbed for influenza testing, and all were included in a test-negative case-control analysis. VE was calculated as (1-odds ratio) × 100. Among 744 patients tested, 382 (51%) were positive for influenza virus: 70% for influenza B, 24% for A(H1N1)pdm09, and 5% for A(H3N2). The overall estimate of VE in preventing laboratory-confirmed influenza was 63% (95% confidence interval (CI): 34 to 79), 55% (1 to 80) in outpatients and 74% (33 to 90) in hospitalized patients. The VE was 70% (41 to 85) against influenza B and 43% (-45 to 78) against influenza A. The VE against virus B was 87% (52 to 96) in hospitalized patients and 56% in outpatients (-5 to 81). Adjusted comparison of vaccination status between inpatient and outpatient cases with influenza B did not show statistically significant differences (odds ratio: 1.13; p = 0.878). These results suggest a high protective effect of the vaccine in the 2012-2013 season, with no differences found for the effect between outpatient and hospitalized cases.

Authors+Show Affiliations

a Instituto de Salud Pública de Navarra ; Pamplona , Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25996366

Citation

Martínez-Baz, Iván, et al. "Influenza Vaccine Effectiveness in Preventing Inpatient and Outpatient Cases in a Season Dominated By Vaccine-matched Influenza B Virus." Human Vaccines & Immunotherapeutics, vol. 11, no. 7, 2015, pp. 1626-33.
Martínez-Baz I, Navascués A, Pozo F, et al. Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus. Hum Vaccin Immunother. 2015;11(7):1626-33.
Martínez-Baz, I., Navascués, A., Pozo, F., Chamorro, J., Albeniz, E., Casado, I., Reina, G., Cenoz, M. G., Ezpeleta, C., & Castilla, J. (2015). Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus. Human Vaccines & Immunotherapeutics, 11(7), 1626-33. https://doi.org/10.1080/21645515.2015.1038002
Martínez-Baz I, et al. Influenza Vaccine Effectiveness in Preventing Inpatient and Outpatient Cases in a Season Dominated By Vaccine-matched Influenza B Virus. Hum Vaccin Immunother. 2015;11(7):1626-33. PubMed PMID: 25996366.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus. AU - Martínez-Baz,Iván, AU - Navascués,Ana, AU - Pozo,Francisco, AU - Chamorro,Judith, AU - Albeniz,Esther, AU - Casado,Itziar, AU - Reina,Gabriel, AU - Cenoz,Manuel García, AU - Ezpeleta,Carmen, AU - Castilla,Jesús, AU - ,, PY - 2015/5/22/entrez PY - 2015/5/23/pubmed PY - 2016/5/10/medline KW - CI, confidence interval KW - ILI, influenza-like illness KW - OR, odds ratio KW - RT-PCR, reverse transcription polymerase chain reaction KW - VE, vaccine effectiveness KW - case-control study KW - effectiveness KW - influenza KW - influenza B virus KW - influenza vaccine KW - sentinel surveillance SP - 1626 EP - 33 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 11 IS - 7 N2 - Studies that have evaluated the influenza vaccine effectiveness (VE) to prevent laboratory-confirmed influenza B cases are uncommon, and few have analyzed the effect in preventing hospitalized cases. We have evaluated the influenza VE in preventing outpatient and hospitalized cases with laboratory-confirmed influenza in the 2012-2013 season, which was dominated by a vaccine-matched influenza B virus. In the population covered by the Navarra Health Service, all hospitalized patients with influenza-like illness (ILI) and all ILI patients attended by a sentinel network of general practitioners were swabbed for influenza testing, and all were included in a test-negative case-control analysis. VE was calculated as (1-odds ratio) × 100. Among 744 patients tested, 382 (51%) were positive for influenza virus: 70% for influenza B, 24% for A(H1N1)pdm09, and 5% for A(H3N2). The overall estimate of VE in preventing laboratory-confirmed influenza was 63% (95% confidence interval (CI): 34 to 79), 55% (1 to 80) in outpatients and 74% (33 to 90) in hospitalized patients. The VE was 70% (41 to 85) against influenza B and 43% (-45 to 78) against influenza A. The VE against virus B was 87% (52 to 96) in hospitalized patients and 56% in outpatients (-5 to 81). Adjusted comparison of vaccination status between inpatient and outpatient cases with influenza B did not show statistically significant differences (odds ratio: 1.13; p = 0.878). These results suggest a high protective effect of the vaccine in the 2012-2013 season, with no differences found for the effect between outpatient and hospitalized cases. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/25996366/Influenza_vaccine_effectiveness_in_preventing_inpatient_and_outpatient_cases_in_a_season_dominated_by_vaccine_matched_influenza_B_virus_ L2 - http://www.tandfonline.com/doi/full/10.1080/21645515.2015.1038002 DB - PRIME DP - Unbound Medicine ER -